MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 128768 | Name: Pranlukast hemihydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of G protein-coupled receptors, CysLT1 and CysLT2.

Chemical Structure

Pranlukast hemihydrate
Pranlukast hemihydrate
CAS#150821-03-7 (hemihydrate)

Theoretical Analysis

MedKoo Cat#: 128768

Name: Pranlukast hemihydrate

CAS#: 150821-03-7 (hemihydrate)

Chemical Formula: C27H25N5O5

Exact Mass: 499.1856

Molecular Weight: 499.53

Elemental Analysis: C, 64.92; H, 5.04; N, 14.02; O, 16.01

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
250mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
150821-03-7 (hemihydrate) 103177-37-3 (free base)
Synonym
Pranlukast hemihydrate; Pranlukast; Ono-1078; ONO 1078; ONO-1078; ONO-RS 411; ONO-RS-411; SB 205312;
IUPAC/Chemical Name
N-(4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl)-4-(4-phenylbutoxy)benzamide hydrate
InChi Key
BNGZNZUNROGDHT-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H23N5O4.H2O/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2
SMILES Code
O=C(C1=CC=C(OCCCCC2=CC=CC=C2)C=C1)NC3=C4C(C(C=C(C5=NN=NN5)O4)=O)=CC=C3.O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 499.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wen X, Chen M, Li Z, Liu W, Xu K, Wang J, Zhao X. Site-specific immobilization of Cysteinyl leukotriene receptor 1 through enzymatic DNA-protein conjugation strategy for lead screening. J Chromatogr A. 2024 Jul 19;1727:464948. doi: 10.1016/j.chroma.2024.464948. Epub 2024 Apr 27. PMID: 38759460. 2: Rajmani RS, Surolia A. Antimycobacterial and healing effects of Pranlukast against MTB infection and pathogenesis in a preclinical mouse model of tuberculosis. Front Immunol. 2024 May 2;15:1347045. doi: 10.3389/fimmu.2024.1347045. PMID: 38756781; PMCID: PMC11096513. 3: Yang K, Gao R, Chen H, Hu J, Zhang P, Wei X, Shi J, Chen Y, Zhang L, Chen J, Lyu Y, Dong Z, Wei W, Hu K, Guo Y, Ge J, Sun A. Myocardial reperfusion injury exacerbation due to ALDH2 deficiency is mediated by neutrophil extracellular traps and prevented by leukotriene C4 inhibition. Eur Heart J. 2024 May 13;45(18):1662-1680. doi: 10.1093/eurheartj/ehae205. PMID: 38666340; PMCID: PMC11089336. 4: Sharma V, Sharma A, Wadje BN, Bharate SB. Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA-approved drugs and clinical candidates. Med Res Rev. 2024 Sep;44(5):2035-2077. doi: 10.1002/med.22032. Epub 2024 Mar 26. PMID: 38532246. 5: Kohno T, Kinoshita J, Oyama K, Saito H, Shimada M, Tsuji T, Yamamoto D, Moriyama H, Inaki N, Ohta T. Chemoprevention of esophageal adenocarcinoma in a rat surgical model by a cysteinyl leukotriene receptor‑1 antagonist. Oncol Lett. 2024 Feb 8;27(4):147. doi: 10.3892/ol.2024.14280. PMID: 38385106; PMCID: PMC10879961. 6: Chen X, Li C, Wang Z, Zhou Y, Chu M. Computational screening of biomarkers and potential drugs for arthrofibrosis based on combination of sequencing and large nature language model. J Orthop Translat. 2024 Jan 20;44:102-113. doi: 10.1016/j.jot.2023.11.002. PMID: 38304615; PMCID: PMC10831815. 7: Kim JH, Lee H, Jeong D, Lee JH, Kwon HS, Song WJ, Cho YS, Kim YJ, Shin YW, Kim TB. The Risk of Neuropsychiatric Adverse Events With Use of Leukotriene Receptor Antagonists in Patients With Asthma: Analysis of Korea's National Health Insurance Sharing Service Database. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3690-3699.e7. doi: 10.1016/j.jaip.2023.08.037. Epub 2023 Sep 1. PMID: 37660732. 8: Cheff DM, Cheng Q, Guo H, Travers J, Klumpp-Thomas C, Shen M, Arnér ESJ, Hall MD. Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4. Redox Biol. 2023 Jul;63:102719. doi: 10.1016/j.redox.2023.102719. Epub 2023 May 16. PMID: 37244126; PMCID: PMC10220285. 9: Tang H, Zhu HL, Zhong JX, Wang MN, Xue YP, Zheng YG. Efficient Production of 3-Amino-2-Hydroxy Acetophenone by Multi-Enzyme Biosynthesis. Chembiochem. 2023 Jun 15;24(12):e202300165. doi: 10.1002/cbic.202300165. Epub 2023 May 25. PMID: 37170827. 10: Frątczak A, Polak K, Miziołek B, Bergler-Czop B. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis. Acta Dermatovenerol Croat. 2022 Sep;30(2):116-118. PMID: 36254546. 11: Prajapati KJ, Kothari CS. Isolation, Characterization, and Toxicity Study of Stress Degradation Products of Pranlukast Hydrate. Chem Res Toxicol. 2022 Jul 18;35(7):1206-1219. doi: 10.1021/acs.chemrestox.1c00222. Epub 2022 Jun 22. PMID: 35731702. 12: Hassan M, Yasir M, Shahzadi S, Kloczkowski A. Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies. ACS Omega. 2022 Jun 1;7(23):19243-19260. doi: 10.1021/acsomega.2c00518. PMID: 35721972; PMCID: PMC9202290. 13: Yu S, Chen X, Li X, Yan J, Jiang Y. Neuroprotective effects of CysLTR antagonist on Streptococcus pneumoniae-induced meningitis in rats. Exp Ther Med. 2022 May 13;24(1):443. doi: 10.3892/etm.2022.11370. PMID: 35720636; PMCID: PMC9185808. 14: Kubota J, Takahashi S, Suzuki T, Ito A, Akiyama N, Takahata N. Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection. PLoS One. 2022 May 27;17(5):e0269043. doi: 10.1371/journal.pone.0269043. PMID: 35622830; PMCID: PMC9140240. 15: Hatakeyama S, Goto M, Yamamoto A, Ogura J, Watanabe N, Tsutsumi S, Yakuwa N, Yamane R, Nagase S, Takahashi K, Kosaki R, Murashima A, Yamaguchi H. The safety of pranlukast and montelukast during the first trimester of pregnancy: A prospective, two-centered cohort study in Japan. Congenit Anom (Kyoto). 2022 Jul;62(4):161-168. doi: 10.1111/cga.12471. Epub 2022 May 24. PMID: 35538631. 16: Shen Y, Mehrabi Nasab E, Hassanpour F, Athari SS. The Effects of Combined Therapeutic Protocol on Allergic Rhinitis Symptoms and Molecular Determinants. Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):141-150. doi: 10.18502/ijaai.v21i2.9222. PMID: 35490268. 17: Shin EY, Jin JH, Kang MK, Yoo YS, Lee JH, Song WJ, Kwon HS, Cho YS, Moon HB, Kim TB. Adverse drug reactions of montelukast and pranlukast: Analysis of the Korea database. Asian Pac J Allergy Immunol. 2022 Mar 12. doi: 10.12932/AP-030821-1202. Epub ahead of print. PMID: 35278057. 18: Yelamanchi SD, Arun Kumar ST, Mishra A, Keshava Prasad TS, Surolia A. Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis. Molecules. 2022 Feb 24;27(5):1520. doi: 10.3390/molecules27051520. PMID: 35268621; PMCID: PMC8911922. 19: Figueroa EE, Denton JS. A SWELL time to develop the molecular pharmacology of the volume-regulated anion channel (VRAC). Channels (Austin). 2022 Dec;16(1):27-36. doi: 10.1080/19336950.2022.2033511. PMID: 35114895; PMCID: PMC8820792. 20: Fujimori K, Uno S, Kuroda K, Matsumoto C, Maehara T. Leukotriene C4 synthase is a novel PPARγ target gene, and leukotriene C4 and D4 activate adipogenesis through cysteinyl LT1 receptors in adipocytes. Biochim Biophys Acta Mol Cell Res. 2022 Mar;1869(3):119203. doi: 10.1016/j.bbamcr.2021.119203. Epub 2021 Dec 27. PMID: 34968576.